The number of people dying from bowel cancer in the UK has dropped more than 30 percent in the last 20 years, show new figures released by Cancer Research UK.
News
NICE turns down kidney cancer drugs
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
GSK walks away from Ionis antisense drugs
GlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals’ experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp.
Councils plea for more cash to combat childhood diabetes
Local councils are calling for “urgent action” on obesity on the back of data showing that more than 600 children and teenagers are now being treated for type II diabetes, which is largely preventable and normally only seen in adults aged over 40 years.
Audit shows drop in hospital heart failure deaths
The latest national heart failure audit has found a significant downturn in the mortality rate among heart failure patients admitted to hospital over the past year, but says the number of deaths remains too high as does the variation in care between trusts.
NHS ‘unsustainable’, says Confederation chief
New figures show over 4 million waiting for surgery
£2m UK consortium to tackle gene therapy
Collaboration will be led by Oxford BioMedica
Alexion and Sema4 partner in rare disease diagnostics
Collaboration will also investigate genomic shields
Cancer Research UK and Biotecnol to trial new immunotherapy
Experimental treatment to target advanced lung tumours
Positive outlook for biotech M&A and funding, says report
M&A, investment and digital health strong for the first half of 2017
Biotech to drive biggest cancer advancements in decades – report
Small companies could introduce a “golden age” of next-gen therapies like CAR-T, combination therapies, and immunotherapy
NICE approves Bayer’s Nexavar for primary liver cancer
Drug was previously only available on the Cancer Drugs Fund
Market access a critical pillar for commercial success
Value based communications, designing innovative commercial deals and value added services are all important elements to engage budget holders in today’s NHS. And with access and uptake of medicines getting tougher on companies, market access is an important part of the marketing mix.
Sanofi files patent infringement suit against MSD in US
Suit relates to Lantus patents and Merck’s follow-on biologic
Judge rules against NHS in Kuvan funding case
The health service refused to fund Biomarin’s PKU drug for a young boy
